Amenamevir

Summary

Amenamevir (CHEMBL4297592) is an approved small molecule (ATC J05AX26); indicated across 4 conditions including herpes zoster and viral infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AX26
• Indications: 4 conditions
• Clinical trials: 12
• Chemistry: 482.6 Da · C24H26N4O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297592
Name	Amenamevir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	11397521
ATC	J05AX26
Molecular formula	C24H26N4O5S
Molecular weight	482.6
InChIKey	MNHNIVNAFBSLLX-UHFFFAOYSA-N

SMILES: CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4

IUPAC name: N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide

Also known as: Amenamevir, ASP-2151, Asp2151, ASP2151, AMENAMEVIR, Amenamevir; Amenalief

Patent coverage: 71 distinct patent families (163 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
herpes zoster	3	MONDO:0005609	EFO:0006510
viral infectious disease	3	MONDO:0005108	EFO:0000763
herpes simplex infectious disease	3	MONDO:0004609	EFO:1002022
genital herpes	2	MONDO:0005770	EFO:0007282

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01959295	PHASE3	COMPLETED	Phase III Study of ASP2151 in Herpes Simplex Patients
NCT01959841	PHASE3	COMPLETED	Phase III Study of ASP2151 in Herpes Zoster Patients
NCT02209324	PHASE3	COMPLETED	Open-label Study of ASP2151 in Herpes Simplex Patients
NCT00486200	PHASE2	COMPLETED	A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT00487682	PHASE2	COMPLETED	Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
NCT00870441	PHASE1	TERMINATED	Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
NCT02223351	PHASE1	COMPLETED	Drug-Drug Interaction Study: ASP2151 and Ritonavir
NCT02321748	PHASE1	COMPLETED	Drug-Drug Interaction Study: ASP2151 and Montelukast
NCT02369172	PHASE1	COMPLETED	Drug-Drug Interaction Study: ASP2151 and Bupropion
NCT02403635	PHASE1	COMPLETED	Drug-Drug Interaction Study: ASP2151 and Midazolam
NCT02796118	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects
NCT02852876	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).